Updating results

1109 results

Sort: Relevance | Date

Peginterferon alfa and ribavirin for treating chronic hepatitis C in children and young people (TA300)

Evidence-based recommendations on peginterferon alfa and ribavirin (Pegasys) for treating chronic hepatitis C in children and young people

Technology appraisal guidance Published November 2013

Eltrombopag for treating chronic immune (idiopathic) thrombocytopenic purpura (TA293)

Evidence-based recommendations on eltrombopag (Revolade) for treating chronic immune (idiopathic) thrombocytopenic purpura (chronic ITP)

Technology appraisal guidance Published July 2013 Last updated October 2018

Botulinum toxin type A for the prevention of headaches in adults with chronic migraine (TA260)

Evidence-based recommendations on botulinum toxin type A (Botox) for the prevention of headaches in adults with chronic migraine

Technology appraisal guidance Published June 2012

Abiraterone for castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen (TA259)

Evidence-based recommendations on abiraterone (Zytiga) for castration-resistant metastatic prostate cancer in adults previously treated with docetaxel

Technology appraisal guidance Published June 2012 Last updated July 2016

Obinutuzumab in combination with chlorambucil for untreated chronic lymphocytic leukaemia (TA343)

Evidence-based recommendations on obinutuzumab (Gazyvaro) with chlorambucil for treating untreated chronic lymphocytic leukaemia

Technology appraisal guidance Published June 2015

Aflibercept for treating diabetic macular oedema (TA346)

Evidence-based recommendations on aflibercept (Eylea) for treating diabetic macular oedema

Technology appraisal guidance Published July 2015

Ustekinumab for treating active psoriatic arthritis (TA340)

Evidence-based recommendations on ustekinumab (Stelara) for treating active psoriatic arthritis in adults

Technology appraisal guidance Published June 2015 Last updated March 2017

Guidance on the use of trastuzumab for the treatment of advanced breast cancer (TA34)

Evidence-based recommendations on the use of trastuzumab (Herceptin) for the treatment of advanced breast cancer

Technology appraisal guidance Published March 2002

Dual‑chamber pacemakers for symptomatic bradycardia due to sick sinus syndrome without atrioventricular block (TA324)

Evidence-based recommendations on dual-chamber pacemakers for symptomatic bradycardia due to sick sinus syndrome without atrioventricular block

Technology appraisal guidance Published November 2014

Lenalidomide for treating myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality (TA322)

Evidence-based recommendations on lenalidomide (Revlimid) for myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality

Technology appraisal guidance Published September 2014 Last updated June 2019

Dabrafenib for treating unresectable or metastatic BRAF V600 mutation‑positive melanoma (TA321)

Evidence-based recommendations on dabrafenib (Tafinlar) for treating unresectable or metastatic BRAF V600 mutation-positive melanoma

Technology appraisal guidance Published October 2014

Nalmefene for reducing alcohol consumption in people with alcohol dependence (TA325)

Evidence-based recommendations on nalmefene (Selincro) for reducing alcohol consumption in people with alcohol dependence

Technology appraisal guidance Published November 2014

Sofosbuvir for treating chronic hepatitis C (TA330)

Evidence-based recommendations on sofosbuvir (Sovaldi) for treating some types of chronic hepatitis C (HCV)

Technology appraisal guidance Published February 2015

Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (TA329)

Evidence-based recommendations on infliximab (Remicade, Inflectra, Remsima) adalimumab (Humira) and golimumab (Simponi) for ulcerative colitis after..

Technology appraisal guidance Published February 2015

Prasugrel with percutaneous coronary intervention for treating acute coronary syndromes (TA317)

Evidence-based recommendations on prasugrel (Efient) with percutaneous coronary intervention (PCI) for treating acute coronary syndrome (ACS)

Technology appraisal guidance Published July 2014

Implantable cardioverter defibrillators and cardiac resynchronisation therapy for arrhythmias and heart failure (TA314)

Evidence-based recommendations on implantable cardioverter defibrillators (ICDs) and cardiac resynchronisation therapy (CRT) for arrhythmias and heart failure

Technology appraisal guidance Published June 2014

Afatinib for treating epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer (TA310)

Evidence-based recommendations on afatinib (Giotrif) for treating EGFR-TK mutation-positive locally advanced or metastatic non-small-cell lung cancer..

Technology appraisal guidance Published April 2014

Canakinumab for treating systemic juvenile idiopathic arthritis (terminated appraisal) (TA302)

NICE is unable to make a recommendation about the use in the NHS of canakinumab drug name (Ilaris) for systemic juvenile idiopathic arthritis..

Technology appraisal guidance Published November 2013

Teriflunomide for treating relapsing–remitting multiple sclerosis (TA303)

Evidence-based recommendations on teriflunomide (Aubagio) for treating relapsing–remitting multiple sclerosis (RRMS/MS) in adults

Technology appraisal guidance Published January 2014 Last updated June 2014

Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome (TA335)

Evidence-based recommendations on rivaroxaban (Xarelto) for preventing adverse outcomes after acute management of acute coronary syndrome (ACS)

Technology appraisal guidance Published March 2015

Empagliflozin in combination therapy for treating type 2 diabetes (TA336)

Evidence-based recommendations on empagliflozin (Jardiance) in combination therapy for treating type 2 diabetes

Technology appraisal guidance Published March 2015

Regorafenib for metastatic colorectal cancer after treatment for metastatic disease (terminated appraisal) (TA334)

NICE is unable to make recommendations about regorafenib for metastatic colorectal cancer because no evidence submission was received from Bayer for the..

Technology appraisal guidance Published February 2015

Everolimus for preventing organ rejection in liver transplantation (TA348)

Evidence-based recommendations on everolimus (Certican) for preventing organ rejection in people having a liver transplant

Technology appraisal guidance Published July 2015

Vedolizumab for treating moderately to severely active ulcerative colitis (TA342)

Evidence-based recommendations on vedolizumab (Entyvio) for treating moderately to severely active ulcerative colitis in adults

Technology appraisal guidance Published June 2015

Apixaban for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism (TA341)

Evidence-based recommendations on apixaban (Eliquis) for treating and preventing deep vein thrombosis (DVT) or pulmonary embolism

Technology appraisal guidance Published June 2015

Tocilizumab for the treatment of rheumatoid arthritis (TA247)

Evidence-based recommendations on tocilizumab (RoActemra) for treating rheumatoid arthritis

Technology appraisal guidance Published February 2012

Romiplostim for the treatment of chronic immune (idiopathic) thrombocytopenic purpura (TA221)

Evidence-based recommendations on romiplostim (Nplate) for treating chronic immune (idiopathic) thrombocytopenic purpura (ITP)

Technology appraisal guidance Published April 2011 Last updated October 2018

Guidance on the use of temozolomide for the treatment of recurrent malignant glioma (brain cancer) (TA23)

Evidence-based recommendations on temozolomide (Temodal) for malignant glioma in children over 3 years, young people and adults.

Technology appraisal guidance Published April 2001 Last updated March 2016

Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (TA217)

Evidence-based recommendations on donepezil (Aricept), galantamine (Reminyl), rivastigmine (Exelon) and memantine (Ebixa) for treating Alzheimer's disease

Technology appraisal guidance Published March 2011 Last updated June 2018

Ustekinumab for the treatment of adults with moderate to severe psoriasis (TA180)

Evidence-based recommendations on ustekinumab (Stelara) for treating moderate to severe psoriasis in adults

Technology appraisal guidance Published September 2009 Last updated March 2017

Sunitinib for the treatment of gastrointestinal stromal tumours (TA179)

Evidence-based recommendations on sunitinib (Sutent) for treating gastrointestinal stromal tumours (cancer of stomach/digestive system)

Technology appraisal guidance Published September 2009

Rituximab for the first-line treatment of chronic lymphocytic leukaemia (TA174)

Evidence-based recommendations on rituximab (MabThera) for the first-line treatment of chronic lymphocytic leukaemia (CLL)

Technology appraisal guidance Published July 2009

Bevacizumab (first-line), sorafenib (first- and second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced and/or metastatic renal cell carcinoma (TA178)

Evidence-based recommendations on evacizumab (Avastin), soradenib (Nexavar), sunitinib (Sutent) and temsirolimus (Torisel) for renal cell carcinoma

Technology appraisal guidance Published August 2009

Spinal cord stimulation for chronic pain of neuropathic or ischaemic origin (TA159)

Evidence-based recommendations on spinal cord stimulation (SCS) for chronic pain of neuropathic or ischaemic origin in adults

Technology appraisal guidance Published October 2008

Oseltamivir, amantadine (review) and zanamivir for the prophylaxis of influenza (TA158)

Evidence-based recommendations on oseltamivir (Tamiflu), amantadine (Lysovir, Symmetrel) and zanamivir (Relenza) to prevent influenza (flu)

Technology appraisal guidance Published September 2008

Dabigatran etexilate for the prevention of venous thromboembolism after hip or knee replacement surgery in adults (TA157)

Evidence-based recommendations on dabigatran etexilate (Pradaxa) for the prevention of venous thromboembolism after hip or knee replacement surgery

Technology appraisal guidance Published September 2008

Ranibizumab and pegaptanib for the treatment of age-related macular degeneration (TA155)

Evidence-based recommendations on ranibizumab (Lucentis) and pegaptanib (Macugen) for the treatment of age-related macular degeneration (AMD)

Technology appraisal guidance Published August 2008 Last updated May 2012

Telbivudine for the treatment of chronic hepatitis B (TA154)

Evidence-based recommendations on telbivudine (Sebivo) for the treatment of chronic hepatitis B

Technology appraisal guidance Published August 2008

Entecavir for the treatment of chronic hepatitis B (TA153)

Evidence-based recommendations on entecavir (Baraclude) for the treatment of chronic hepatitis B

Technology appraisal guidance Published August 2008

Continuous subcutaneous insulin infusion for the treatment of diabetes mellitus (TA151)

Evidence-based recommendations on continuous subcutaneous insulin infusion for the treatment of diabetes mellitus

Technology appraisal guidance Published July 2008

Carmustine implants for the treatment of recurrent glioblastoma multiforme (terminated appraisal) (TA149)

NICE is unable to make a recommendation about the use in the NHS of carmustine implants because no evidence submission was received from the

Technology appraisal guidance Published June 2008

Bevacizumab for the treatment of non-small-cell lung cancer (terminated appraisal) (TA148)

NICE is unable to make a recommendation about the use in the NHS of bevacizumab for treating non-small-cell lung cancer (NSCLC)

Technology appraisal guidance Published June 2008

Cetuximab for the treatment of locally advanced squamous cell cancer of the head and neck (TA145)

Evidence-based recommendations on cetuximab (Erbitux) for the treatment of locally advanced squamous cell cancer of the head and neck

Technology appraisal guidance Published June 2008

Carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma (TA121)

Evidence-based recommendations on carmustine implants Gliadel) and temozolomide (Temodal) for newly diagnosed high-grade glioma (brain tumour)

Technology appraisal guidance Published June 2007

Fludarabine monotherapy for the first-line treatment of chronic lymphocytic leukaemia (TA119)

Evidence-based recommendations on fludarabine (Fludara) monotherapy for the first-line treatment of chronic lymphocytic leukaemia (CLL)

Technology appraisal guidance Published February 2007

Cinacalcet for the treatment of secondary hyperparathyroidism in patients with end-stage renal disease on maintenance dialysis therapy (TA117)

Evidence-based recommendations on cinacalcet (Mimpara) for treating secondary hyperparathyroidism to treat people on dialysis who have kidney disease

Technology appraisal guidance Published January 2007

Gemcitabine for the treatment of metastatic breast cancer (TA116)

Evidence-based recommendations on gemcitabine (Gemzar) for treating metastatic breast cancer

Technology appraisal guidance Published January 2007

Naltrexone for the management of opioid dependence (TA115)

Evidence-based recommendations on naltrexone (Nalorex) for the management of opioid dependence

Technology appraisal guidance Published January 2007

Amantadine, oseltamivir and zanamivir for the treatment of influenza (TA168)

Evidence-based recommendations on amantadine (Lysovir, Symmetrel), oseltamivir (Tamiflu) and zanamivir (Relenza) for treating influenza (flu)

Technology appraisal guidance Published February 2009

Rivaroxaban for the prevention of venous thromboembolism after total hip or total knee replacement in adults (TA170)

Evidence-based recommendations on rivaroxaban (Xarelto) for the prevention of venous thromboembolism after total hip or knee replacement in adults

Technology appraisal guidance Published April 2009